|
WO2011130834A1
|
|
Non-intravenous dosage form comprising solid formulation of liquid biologically active agent and uses thereof
|
|
WO2010069050A1
|
|
Misuse preventative, controlled release formulation
|
|
MX2010006694A
|
|
Misuse preventative, controlled release formulation.
|
|
WO2009049405A1
|
|
Bilayer composition for the sustained release of acetaminophen and tramadol
|
|
EP2081548A2
|
|
Compositions and methods for ph targeted drug delivery
|
|
TW200826960A
|
|
Degradable polymeric microsphere composition
|
|
TW200812646A
|
|
Sustained drug release compositions
|
|
TW200812585A
|
|
Trazodone composition for once a day administration
|
|
WO2007073596A1
|
|
Degradable polymeric microsphere composition
|
|
US2007128275A1
|
|
Trazodone composition for once a day administration
|
|
US7262253B2
|
|
Process for the preparation of amphiphilic poly (N-vinyl-2-pyrrolidone) block copolymers
|
|
ZA200504215B
|
|
Controlled-release compositions
|
|
MXPA05004412A
|
|
Sustained-release tramadol formulations with 24-hour efficacy.
|
|
CN1942175A
|
|
Sustained-release tramadol formulations with 24-hour efficacy
|
|
CA2503361A1
|
|
Controlled-release compositions
|
|
WO2004037222A2
|
|
Sustained-release tramadol formulations with 24-hour efficacy
|
|
MY142195A
|
|
Controlled-release compositions
|
|
TWI332848B
|
|
Controlled-release compositions
|
|
US7094810B2
|
|
pH-sensitive block copolymers for pharmaceutical compositions
|
|
US6780324B2
|
|
Preparation of sterile stabilized nanodispersions
|
